These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 22338160)

  • 1. [Screen and analysis of FVIII inhibitors in 167 hemophilia A patients].
    Liu XH; Wang HF; Yang R
    Zhonghua Xue Ye Xue Za Zhi; 2011 Sep; 32(9):627-9. PubMed ID: 22338160
    [No Abstract]   [Full Text] [Related]  

  • 2. One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype.
    Cid AR; Calabuig M; Cortina V; Casaña P; Haya S; Moret A; Cabrera N; Aznar JA
    Haemophilia; 2008 Sep; 14(5):1049-54. PubMed ID: 18540892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Importance of the study of the binding of factor VIII to von Willebrand factor in hemophilia A].
    Batlle J; Blanco-López MJ; Castiñeira MP; López-Fernández MF
    Sangre (Barc); 1992 Jun; 37(3):211-24. PubMed ID: 1359656
    [No Abstract]   [Full Text] [Related]  

  • 4. Assaying FVIII activity: one method is not enough, and never was.
    Makris M; Peyvandi F
    Haemophilia; 2014 May; 20(3):301-3. PubMed ID: 24731127
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.
    Orsini F; Rotschild C; Beurrier P; Faradji A; Goudemand J; Polack B
    Haematologica; 2005 Sep; 90(9):1288-90. PubMed ID: 16154861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and course of inhibitors among patients with classic hemophilia.
    Kasper CK
    Thromb Diath Haemorrh; 1973 Nov; 30(2):263-71. PubMed ID: 4773365
    [No Abstract]   [Full Text] [Related]  

  • 7. Normalization of factor VIII levels in a patient with mild haemophilia A during a 35-year period.
    Mainwaring CJ; Evans J; Chana J; Lewis H
    Haemophilia; 2006 Nov; 12(6):668-71. PubMed ID: 17083519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes.
    Suzuki H; Shima M; Arai M; Kagawa K; Fukutake K; Kamisue S; Nakai H; Morichika S; Tanaka I; Inoue M; Gale K; Tuddenham EG; Yoshioka A
    Thromb Haemost; 1997 May; 77(5):862-7. PubMed ID: 9184393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. von Willebrand disease masquerading as haemophilia A.
    Mazurier C
    Thromb Haemost; 1992 Apr; 67(4):391-6. PubMed ID: 1631785
    [No Abstract]   [Full Text] [Related]  

  • 10. Molecular pathology of haemophilia A in Indian patients: identification of 11 novel mutations.
    Nair PS; Shetty S; Kulkarni B; Ghosh K
    Clin Chim Acta; 2010 Dec; 411(23-24):2004-8. PubMed ID: 20800587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mild hemophilia A.
    Franchini M; Favaloro EJ; Lippi G
    J Thromb Haemost; 2010 Mar; 8(3):421-32. PubMed ID: 19995408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The humoral response to human factor VIII in hemophilia A mice.
    Healey JF; Parker ET; Barrow RT; Langley TJ; Church WR; Lollar P
    J Thromb Haemost; 2007 Mar; 5(3):512-9. PubMed ID: 17181826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gene diagnosis of hemophilia A].
    Shen Y
    Zhonghua Yi Xue Za Zhi; 1989 Aug; 69(8):422-6, 30. PubMed ID: 2575928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
    Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
    Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia.
    Wootla B; Mahendra A; Dimitrov JD; Friboulet A; Borel-Derlon A; Rao DN; Uda T; Borg JY; Bayry J; Kaveri SV; Lacroix-Desmazes S
    FEBS Lett; 2009 Aug; 583(15):2565-72. PubMed ID: 19595998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens.
    Lin PC; Liao YM; Tsai SP; Chang TT
    Pediatr Blood Cancer; 2011 Dec; 57(6):1029-33. PubMed ID: 21793191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor VIII (FVIII) gene mutations in 120 patients with hemophilia A: detection of 26 novel mutations and correlation with FVIII inhibitor development.
    Repessé Y; Slaoui M; Ferrandiz D; Gautier P; Costa C; Costa JM; Lavergne JM; Borel-Derlon A
    J Thromb Haemost; 2007 Jul; 5(7):1469-76. PubMed ID: 17445092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype.
    Trossaërt M; Regnault V; Sigaud M; Boisseau P; Fressinaud E; Lecompte T
    J Thromb Haemost; 2008 Mar; 6(3):486-93. PubMed ID: 18047548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prenatal diagnosis of hemophilia A, presenting a new mutation in the FVIII gene.
    He Z; Chen S; Jiang W
    Blood Cells Mol Dis; 2010; 44(2):124-5. PubMed ID: 20018532
    [No Abstract]   [Full Text] [Related]  

  • 20. Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A.
    Ninivaggi M; Dargaud Y; van Oerle R; de Laat B; Hemker HC; Lindhout T
    J Thromb Haemost; 2011 Aug; 9(8):1549-55. PubMed ID: 21605333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.